Enhancing Prospective Thinking in Early Recovery (BEAM)
Enhancing Prospective Thinking in Early Recovery
Indiana University
21 participants
Jun 17, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to test the prosocial effects of personally-relevant, high-intensity episodic future-thinking (EFT) cues in alcohol use disorder persons and related brain mechanisms. The main question\[s\] this trial aims to answer are: * Will high-intensity EFT cues will produce greater delayed reward preference than low-intensity cues? * Will high-intensity EFT cues effect greater treatment-seeking interest? * Will high-intensity EFT cues elicit greater response in regions for prospective thinking during delay discounting (vs. low-intensity) * Will nucleus accumbens-precuneus resting connectivity correlate with behavioral SS? * Will the novel behavioral SS decision-making task activate the nucleus accumbens? Researchers will compare the experimental (high-intensity group) and control (low-intensity) groups to see if there are differences in the results for the questions outlined above.
Eligibility
Inclusion Criteria2
- Individuals who meet current heavy drinking (≥2 heavy drinking days/month OR ≥7 drinks/week for biological females, and ≥14 drinks/week if biological male \[NIAAA definition\] and/or AUDIT scores ≥8)
- English comprehension
Exclusion Criteria4
- Unstable medical disorders
- Outside the age range of 18-60
- Smell/taste disorders
- Unstable psychiatric conditions
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06283472